Stage and organ dependent effects of 1-O-hexyl-2,3,5-trimethylhydroquinone, ascorbic acid derivatives, n-heptadecane-8-10-dione and phenylethyl isothiocyanate in a rat multiorgan carcinogenesis model.
The effects of 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), phenylethylisothiocyanate (PEITC), 3-O-ethylascorbic acid, 3-O-dodecylcarbomethylascorbic acid and n-heptadecane-8, 10-dione were analyzed in a rat multiorgan carcinogenesis model. Groups of 15 animals were given a single intraperitoneal (i.p.) injection of diethylnitrosamine and 4 i.p. injections of N-methylnitrosourea as well as N-butyl-N-(4-hydroxybutyl) nitrosamine in the drinking water during the first 2 weeks. Then 4 subcutaneous (s.c.) injections of dimethylhydrazine and 2,2'-dihydroxy-di-n-propylnitrosamine were given in the drinking water over the next 2 weeks for initiation. Test compounds were administered during the initiation or post-initiation periods. The dietary dose was 1% except for n-heptadecane-8, 10-dione and PEITC (0.1%). Complete autopsy was performed at the end of experimental week 28. All 5 compounds reduced the number of lung hyperplasia, particularly PEITC when given during the initiation period. In addition, HTHQ lowered the incidence of esophageal hyperplasia in the initiation period, and of small and large intestinal adenomas in the post-initiation period. However, it also enhanced the development of hyperplasia and papilloma in the forestomach and tongue. PEITC lowered the induction of esophageal hyperplasia, kidney atypical tubules and liver glutathione S-transferase placental form (GST-P)-positive foci when given during the initiation period but enhanced the development of liver GST-P positive foci and urinary bladder tumors in the post-initiation period. Moreover, it induced hyperplasia of the urinary bladder. Our results indicate minor adverse effects for HTHQ in the forestomach and tongue, and demonstrate that PEITC, which inhibits carcinogenesis at the initiation stage in several organs, also exhibits promotion potential in liver and urinary bladder in the post-initiation stage under the present experimental conditions.
Ogawa
K
K
First Department of Pathology, Nagoya City University Medical School, Japan. kogawa@med.nagoya-cu.ac.jp
Futakuchi
M
M
Hirose
M
M
Boonyaphiphat
P
P
Mizoguchi
Y
Y
Miki
T
T
Shirai
T
T
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D005982:Glutathione Transferase / Q000378:metabolism; D006873:Hydroquinones / Q000627:therapeutic use; D017879:Isothiocyanates / Q000627:therapeutic use*; D008297:Male; D009367:Neoplasm Staging; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D009928:Organ Specificity; D011230:Precancerous Conditions / Q000188:drug therapy; D051381:Rats; D011916:Rats, Inbred F344
D016588:Anticarcinogenic Agents; D006873:Hydroquinones; D017879:Isothiocyanates; C058305:phenethyl isothiocyanate; C081906:1-O-hexyl-2,3,5-trimethylhydroquinone; D005982:Glutathione Transferase; D001205:Ascorbic Acid